Grunenthal 
Welcome,         Profile    Billing    Logout  
 15 Products   72 Diseases  15 Products   62 Trials   1500 News 
90 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
cebranopadol (TRN-228) / Tris Pharma
ALLEVIATE-2, NCT06423703: A Study of Cebranopadol for the Treatment of Acute Pain After Bunionectomy

Recruiting
3
240
US
Cebranopadol, Oxycodone IR, Placebo
Tris Pharma, Inc.
Acute Pain
02/25
03/25
ALLEVIATE-1, NCT06545097: A Study of Cebranopadol for the Treatment of Acute Pain After Abdominoplasty

Active, not recruiting
3
300
US
Cebranopadol, Placebo
Tris Pharma, Inc.
Acute Pain
12/24
02/25
NCT05491785: Cebranopadol Effects on Ventilatory Drive, Central Nervous System (CNS) and Pain.

Completed
1
30
Europe
Cebranopadol 600 µg, Experimental, Cebranopadol 800 µg, Cebranopadol 1000 µg, Oxycodone 30 mg, Active Comparator, Oxycodone 60 mg, Placebo, Placebo comparator
Tris Pharma, Inc.
Pain
03/23
01/24
NCT06453265: A Study to Assess the Abuse Potential of Intranasal Cebranopadol

Active, not recruiting
1
45
US
Cebranopadol- 600 ug, Cebranopadol- 800ug, Cebranopadol- 1000ug, Treatment A:, Treatment B, Treatment C, Qualification
Tris Pharma, Inc.
Abuse, Drug
11/24
03/25
Nucynta (tapentadol) / Collegium Pharma, Grunenthal
2010-023175-26: Influence of Tapentadol on endogenous modulation of pain in chronic neuropathic pain patients and healthy volunteers

Ongoing
4
24
Europe
Tapentadol, morphine, Tapentadol, morphine, Tapentadol, morphine
Leiden University Medical Center
Chronic pain patients/ mhealthy volunteers
 
 
2015-005259-28: A study on the efefct of the analgesic tapentadol on pain scores in patients with low back pain

Ongoing
4
40
Europe
Tapentadol, N02AX06, Tablet, Palexia
LUMC, LUMC, Grunenthal
Low back pain, pain in the back, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
2015-005258-37: Effect of treatment with the painkiller tapentadol on pain in patients with fibromyalgia

Ongoing
4
40
Europe
Tapenatdol, N02AX06, Tablet, Pallexia
LUMC, LUMC, Grunenthal GmbH
Fibromyalgia, Fibromyalgia, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
2018-003515-22: Breathing effects of two opioid pain killers in healthy volunteers

Not yet recruiting
4
24
Europe
Tapentadol, Oxycodone, N02AX06, RVG110728, Tablet, Pallexia, Oxycodone
Leiden University Medical Center, Grunenthal
Chronic pain, Chronic pain, Body processes [G] - Physiological processes [G07]
 
 
2018-004804-21: The prevention of chronic postoperative pain.

Not yet recruiting
4
540
Europe
Tapentadol, Tablet, Tapentadol
Leiden University Medical Center, Grunenthal
Chronic pain after inguinal hernia surgery and knee replacement surgery., Chronic pain after surgery., Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03]
 
 
NCT06269770: Tapentadol vs Tramadol in Total Knee Arthroplasty

Recruiting
4
96
Europe
Tapentadol, Tramadol
University of Thessaly
Total Knee Replacement, Post-operative Pain, Chronic Pain
05/25
06/25
2006-004514-40: A Randomized, Double-Blind, Active- And Placebo-Controlled, Parallel Group, Multicenter Study To Evaluate The Efficacy And Safety of Multiple Doses of CG5503 Immediate Release Formulation In Subjects Awaiting Primary Joint Replacement Surgery for End-Stage Joint Disease

Ongoing
3
100
Europe
CG5503; R331333, OxyNorm, CG5503; R331333, n.a., OxyNorm 5, 10, 20 mg, OxyNorm 5, 10, 20 mg
Johnson & Johnson Pharamceutical Research & Development, L.L.C.
Pain
 
 
ChiCTR2300069799: Efficacy and Safety of Tapentadol Hydrochloride Tablets in Subjects with Moderate to Severe Pain after Orthopedic Surgery: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Phase III Study

Not yet recruiting
3
286
 
Oral administration Tapentadol Hydrochloride tablets ;Oral administration Oxycodone hydrochloride capsules
The Third Xiangya Hospital of Central South University; Third Xiangya Hospital of Central South University, Jiangsu Enhua Pharmaceutical Co., LTD., National Natural Science Foundation of China, Hunan Natural Science Foundation, Self-funded
Postoperative pain
 
 
2019-000755-14: Trial in healthy subjects to investigate the effect of analgesic drug on pain processing observed by non-invasive neurophysiological measurements of human spinal cord and brainstem activity. Studio su soggetti sani volto ad indagare gli effetti di farmaci analgesici sulla elaborazione del dolore mediante misure neurofisiologiche del'attività del midollo del midollo spinale e del tronco dell'encefalo

Ongoing
2
56
Europe
pregabalin, lacosamide, tapentadol, [N03AX16], [N/A], [N02AX06], Capsule, hard, Film-coated tablet, Tablet, LYRICA - 75 MG CAPSULA RIGIDA - USO ORALE 100 CAPSULE IN BLISTER IN UNITA' SEPARABILI PERFORATO (PVC/ALU), VIMPAT - 100 MG - COMPRESSE RIVESTITE CON FILM - USO ORALE - BLISTER (PVC/PVDC/ALU) 14 COMPRESSE, PALEXIA - 50 MG COMPRESSE RIVESTITE CON FILM 10 COMPRESSE IN BLISTER PVC/PVDC/AL
UMBERTO I - POLICLINICO DI ROMA, Teva Pharmaceutical Industries LTD, Innovative Medicines Initiative 2 (IMI2) Joint Undertaking under grant agreement, Eli Lilly and Company LTD, Esteve Pharmaceuticals SA, Grünenthal GmbH
Healthy volunteers (intended indication: pain) soggetti sani (indicazione: dolore), Healthy volunteers (intended indication: pain) soggetti sani (indicazione: dolore), Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03]
 
 
2019-000942-36: The effects of lacosamide, pregabalin and tapentadol on biomarkers of peripheral pain processing

Not yet recruiting
2
60
Europe
lacosamide, Pregabalin, Tapentadol, [N02AX06], [N/A], [N03AX16], Tablet, Capsule, Vimpat 100 mg film coated tablets, Lyrica 75 mg hard capsules, Palexia 50 mg film-coated tablets
Aarhus University, UMBERTO I - POLICLINICO DI ROMA, Innovative Medicines Initiative 2 (IMI2) Joint Undertaking under grant agreement, Eli Lilly and Company LTD, Esteve Pharmaceuticals SA, Grünenthal GmbH, Teva Pharmaceutical Industries LTD
Healthy volunteers (intended indication: pain), Study in healthy volunteers to examine drug effects on biomarkers in experimental pain, Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03]
 
 
2019-001204-37: The effects of lacosamide, pregabalin and tapentadol on biomarkers of pain processing

Not yet recruiting
2
56
Europe
lacosamide, pregabalin, tapentadol, [N02AX06], [N03AX16], [N/A], Film-coated tablet, Capsule, Tablet, Vimpat 100mg film coated tablets, Lyrica 75 mg hard capsules, Palexia 50 mg film-coated tablets
Institute of Neuroscience (IoNS), Université catholique de Louvain, UMBERTO I - POLICLINICO DI ROMA, Innovative Medicines Initiative 2 (IMI2) Joint Undertaking under Grant Agreement, Eli Lilly and Company LTD, Esteve Pharmaceuticals SA, Grünenthal GmBH, Teva Pharmaceutical Industries LTD
Healthy subjects (intended indication: pain), Study in healthy subjects to examine drug effects on biomarkers in experimental pain, Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03]
 
 
Qutenza (capsaicin) / Grunenthal, LTS Lohmann Therapy Systems
2012-002406-46: Comparison of different Capsaicin doses and their effects on nerve fibres in the skin Vergleich unterschiedlicher Capsaicin Dosierungen und ihr Einfluss auf die Nervenfasern in der Haut

Ongoing
4
12
Europe
Qutenza, Capsaicin 0,05% Ointment, N01BX04, Qutenza, Qutenza
Medizinische Universität Wien, Universitätsklinik für Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie, Medizinische Universität Wien
Impact of Capsaicin on epidermal nerve fibres Einfluss von Capsaicin auf epidermale Nervenfasern
 
 
2013-002546-36: Painthresholds under high-dose topical Capsaicin

Ongoing
4
20
Europe
Qutenza, Qutenza, Qutenza
Medizinische Universität Wien, Universitätsklinik für Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie, Medizinische Universität Wien, Universitätsklinik für Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie
Pain
 
 
2017-004746-17: Treatment of nerve pain in patients with diabetes with a capsaicin (chilli pepper) patch (skin plaster).

Ongoing
4
50
Europe
Qutenza (Capsaicin) 8 % patch, Cutaneous patch, Qutenza (Capsaicin) 8 % patch
Joint Research Compliance Office, Imperial College London and Imperial College Healthcare NHS Trust, Diabetes UK
Diabetic painful neuropathy, Nerve damage with pain in patients with diabetes, Diseases [C] - Nervous System Diseases [C10]
 
 
2018-003617-17: Localized neuropathic pain: topical treatment versus systemic treatment

Not yet recruiting
4
591
Europe
Cutaneous patch, Capsule, hard, Lidocaïne Grünenthal 700 mg pleister (Versatis), Capsaicine (Qutenza) 179 mg huidpleister, Pregabaline (Lyrica) 75 mg harde capsules
Antwerp University Hospital (UZA), Belgian Health Care Knowledge Center (KCE)
Patients suffering from localized neuropathic pain (LNP), Patients suffering from localized neuropathic pain (LNP), Diseases [C] - Nervous System Diseases [C10]
 
 
2020-001022-57: Treatment with small Qutenza patches over painful trigger points in scars after operation: A blinded study using placebo paths versus active Qutenza patch

Not yet recruiting
4
26
Europe
Qutenza 179 mg cutaneous patch, EMEA/H/C/00909, Cutaneous patch, Qutenza 179 mg kutanplaster
Wojciech Zbigniew Pawlak
Post-operative neuropathic pain, Pain after nerve damage, Diseases [C] - Nervous System Diseases [C10]
 
 
CADOR, NCT06444919: Capsaicin in Digital Osteoarthritis Versus Control

Recruiting
4
120
Europe
Capsaicin 179 Mg Cutaneous Patch, QUTENZA, Capsaicine low dose 0.04 %, control treatment
University Hospital, Clermont-Ferrand, Grünenthal GmbH
Osteoarthritis Hand, Neuropathic Pain
01/28
01/28
2018-003559-39: multicentric Study , open, randomized, comparing the topical treatment by patch of capsaïcine with 8 % ( Qutenza) to the oral prégabaline treatment in the early treatment of the neuropathic pains after a primary surgery for breast cancer ( CAPTRANE) Etude multicentrique, ouverte, randomisée, comparant le traitement topique par patch de capsaïcine à 8% (Qutenza) à la prégabaline per os dans le traitement précoce des douleurs neuropathiques après une chirurgie primaire pour cancer du sein (CAPTRANE)

Not yet recruiting
3
772
Europe
Cutaneous patch, Capsule, QUTENZA, PREGABALINE
INSTITUT DE CANCEROLOGIE DE L'OUEST, GRUNENTHAL
men and /or women older than 18 years with breast cancer for which a surgical operation was realized. homme et/ou femme de plus de 18 ans, atteint d’un cancer du sein pour lequel une intervention chirurgicale a été réalisée., men and /or women older than 18 years with breast cancer for which a surgical operation was realized. homme et/ou femme de plus de 18 ans, atteint d’un cancer du sein pour lequel une intervention chirurgicale a été réalisée., Diseases [C] - Cancer [C04]
 
 
2021-001409-64: A multi site clinical trial to evaluate the efficacy and safety of Qutenza® in subjects with post-surgical neuropathic pain Un ensayo clínico en varios centros para evaluar la eficacia y seguridad de Qutenza® en pacientes con dolor neuropático posquirúrgico

Not yet recruiting
3
510
Europe
Capsaicin, Cutaneous patch, Qutenza
Averitas Pharma, Inc., Averitas Pharma, Inc.
Post-surgical neuropathic pain (PSNP) Dolor neuropático posquirúrgico (DNPQ), Post-surgical neuropathic pain (PSNP) Dolor neuropático posquirúrgico (DNPQ), Body processes [G] - Physiological processes [G07]
 
 
CAPTRANE, NCT03794388: Evaluation in the Treatment of Neuropathic Pain Post Breast Surgery

Completed
3
140
Europe
Capsaicin, qutenza EU/1/09/524/001, Pregabalin, Lyrica
Institut Cancerologie de l'Ouest, Grünenthal GmbH
Breast Cancer Patient
11/22
11/22
NCT04967664 / 2021-001409-64: Comparison of Qutenza (8% Capsaicin) With a Low-dose Capsaicin for Treatment of Nerve Pain After Surgery

Active, not recruiting
3
409
Europe, US
Qutenza (capsaicin) 8% topical system, capsaicin 0.04% topical system
Averitas Pharma, Inc., Averitas Pharma, Inc.
Post Surgical Neuropathic Pain
03/25
08/25
CAPSAPED, NCT05997979: Analgesic Effectiveness of Capsaicin 8% Cutaneous Patch in Children

Recruiting
3
46
Europe
Capsaicin 8% patch, QUTENZA®, Hydrocolloid dressing, COMFEEL PLUS TRANSPARENT
University Hospital, Brest
Neuropathic Pain, Chronic Pain
04/26
04/26
CAPSACOX, NCT06023706: Study Evaluating the Analgesic Efficacy of Capsaicin 8% Patches in Chronic Coccygodynia.

Recruiting
3
188
Europe
Capsaicin 179 Mg Cutaneous Patch, qutenza, Capsaicin low concentration patch (capsaicin 0,04%, 3,2 mg/cm2)
Nantes University Hospital
Coccyx Disorder, Neuropathic Pain, Coccygodynia
01/27
06/27
CAPNEUCHIM, NCT05840562: Capsaicin 179 mg Patch Versus Oral Duloxetine in Patients With Chemotherapy-induced Peripheral Neuropathy

Recruiting
3
274
Europe
Capsaicin, Qutenza, Duloxetine, Cymbalta
Institut Cancerologie de l'Ouest, Grünenthal GmbH
Chemotherapy-induced Peripheral Neuropathy
03/27
03/27
2020-003965-21: Phase II Randomized Controlled Study Aiming to Evaluate the Interest of Qutenza in Patients With ORL Cancer in Remission and With Sequellae Neuropathic Pain. Phase II randomisée comparative visant à évaluer l’intérêt du Qutenza dans la prise en charge de patients en rémission de cancer ORL et présentant des douleurs neuropathiques séquellaires.

Not yet recruiting
2
130
Europe
Cutaneous patch, Oral solution, Qutenza®, Laroxyl®
INSTITUT CLAUDIUS REGAUD, DGOS
Head and neck cancer Cancer ORL, Head and neck cancer Cancer ORL, Diseases [C] - Cancer [C04]
 
 
NCT03464292: Spinal and Supra-Spinal Pain Mechanisms in Patients With Fibromyalgia

Completed
2
55
US
Capsaicin Patch 8% or 0.1% Capsaicin Cream, Qutenza, Capsaicin No-Fuss, Vehicle Patch
University of Florida
Fibromyalgia, Pain
07/23
12/23
SerCaBot, NCT06807164: Serratus Plane Block (SPB) Versus Capsaïcine Versus Botox-A for Chronic Neuropathic Pain in Post-mastectomy Syndrome

Recruiting
2
123
Europe
Capsaicin 8% Patch, Qutenza®, Serratus Plane Block, SPB, Botulinum Toxin A, Botox-A, Botox
Centre Oscar Lambret, Ligue contre le cancer, France, Santelys Association, CTD-CNO, Caen
Post-Mastectomy Neuropathic Pain Syndrome
08/27
12/27
TEC-ORL, NCT04704453 / 2020-003965-21: Study to Evaluate the Interest of Qutenza in Patients With Head and Neck Cancer in Remission and With Sequelae Neuropathic Pain.

Active, not recruiting
2
13
Europe
Capsaïcin patch (Qutenza®), Amitriptyline (Laroxyl®)
Institut Claudius Regaud, DGOS
Head and Neck Cancer
01/26
01/26
NCT06744816: Exploring the Benefit of Topical Capsaicin in Treating Pain From Chemo-induced Peripheral Neuropathy: a Longitudinal Single Center Pilot Study

Not yet recruiting
1
20
US
Qutenza Patch
M.D. Anderson Cancer Center, Averitas Pharma, Inc.
Peripheral Neuropathy Due to Chemotherapy
11/25
11/27
NCT06197529: Is Nociceptive Processing Evoked by Heat Homeostatically Regulated: A Contact-heat Evoked Potentials Study

Completed
N/A
18
Europe
Homeostatic Plasticity, Topical alone (Capsaicin 8% Patch), Qutenza Capsaicin (8%), Placebo Patch, Homeostatic Plasticity (Sham)
Aalborg University
Healthy
03/24
03/24
ALGOS, NCT05726929: Algology in Oncology Osteopathic Support

Completed
N/A
12
Europe
Osteopathic treatment, Capsaicin QUTENZA Patch (TAU)
Institut Toulousain d'Ostéopathie, Institut Claudius Regaud
Breast Cancer, Neuropathic Pain
12/24
12/24
CAPSACOXp, NCT05983263: Analgesic Efficacy of Capsaicin 8% Patch (QUTENZA®) in Coccygodygnia

Not yet recruiting
N/A
106
NA
Capsaicin, Capsaicin 8% patch
Nantes University Hospital
Coccyx Disorder
12/23
12/23
QULOX, NCT05560516: Qutenza Versus Duloxetine in Chemotherapy-induced Peripheral Neuropathy (CIPN)

Recruiting
N/A
102
Europe
Qutenza, Duloxetine
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Leiden University Medical Center, Reinier de Graaf
Qutenza, Duloxetine, Chemotherapy-induced Peripheral Neuropathy, CIPN - Chemotherapy-Induced Peripheral Neuropathy
12/24
12/25
NCT06495424: Observational Study to Evaluate the Efficacy of Sustained QUTENZA® Use in Painful Diabetic Peripheral Neuropathy

Not yet recruiting
N/A
150
NA
Capsaicin 8%
Averitas Pharma, Inc.
Peripheral Diabetic Neuropathy, Painful Diabetic Neuropathy
12/26
03/27
NCT06540456: Qutenza 8% Capsaicin Topical System for the Treatment of Neuropathic Axial Lower Back Pain and Lumbosacral Radiculopathy

Enrolling by invitation
N/A
50
US
Qutenza® 8% Capsaicin Topical System
Medical University of South Carolina, Averitas Pharma, Inc.
Lower Back Pain, Lumbosacral Radiculopathy
07/27
07/28
Palexia RP (tapentadol extended release) / Assertio, J&J, Grunenthal, Collegium Pharma
2017-000141-52: The effect of tapentadol and oxycodone on the human pain system Effekten af tapentadol og oxycodon på det humane smertenetværk

Ongoing
4
20
Europe
Palexia Depot, OxyContin, Modified-release tablet, Palexia Depot, OxyContin
Asbjørn Mohr Drewes, Grünenthal GmBH
Healthy volunteers - pain, Pain, Diseases [C] - Nervous System Diseases [C10]
 
 
2016-005082-31: Assessment of Tapentadol effects on patients with pain central sensitization using functional MRI Evaluación del efecto de tapentadol en pacientes con dolor por sensibilización central utilizando la resonancia magnética funcional (fMRI)

Ongoing
4
40
Europe
Palexia Retard, Palexia retard, Prolonged-release tablet, Palexia retard 50 mg, Palexia retard 100 mg, Palexia retard 150 mg, Palexia retard 200 mg, Palexia retard 250 mg
MRI Research Unit, Radiology Department. Hospital del Mar., Grunenthal Pharma S.A.
Patients suffering from pain due to knee osteoarthritis Pacientes con dolor por artrosis de rodilla, Patients suffering from pain due to knee osteoarthritis Pacientes con dolor por artrosis de rodilla, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
2017-001285-23: A comparison of pain relief and effects on respiration from tapentadol and oxycodone after surgical removal of the uterus.

Not yet recruiting
4
90
Europe
Tablet, Modified-release tablet, Capsule, hard, Palexia® 50 mg, Palexia depot®, OxyNorm®, OxyContin®
Oslo University Hospital, Oslo University Hospital
Pain after laparoscopic hysterectomy., Pain after surgical removal of the uterus using a minimal invasive surgical technique., Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03]
 
 
2009-017470-20: An open-label extension study for patients with severe chronic low back pain or severe chronic pain due to knee osteoarthritis who have completed any of the previous phase IIIb trials with tapentadol hydrochloride, KF5503/42, KF5503/44 or KF5503/45.

Ongoing
3
25
Europe
Tapentadol 50 mg film coated tablet, Tapentadol 50 mg prolonged release tablet, Tapentadol 100 mg prolonged release tablet, Tapentadol 150 mg prolonged release tablet, Tapentadol 200 mg prolonged release tablet, Tapentadol 250 mg prolonged release tablet, CG5503,
Laboratoires Grünenthal
Severe chronic pain
 
 
2022-001358-41: Clinical study to prove that treatment of chronic (non-specific) low back pain with VER-01, a cannabis based medicine, shows benefit compared to treatment with opioids

Not yet recruiting
3
350
Europe
Standardized oleoresin of Cannabis sativa L. folium cum flore, THC-chemotype, Tilidine and Naloxone (50 mg/4 mg) prolonged-release tablets, Tilidine and Naloxone (100 mg/8 mg) prolonged-release tablets, Tramadol 100 mg prolonged-release tablets, Tramadol 200 mg prolonged-release tablets, Fentanyl 12 micrograms/h transdermal patch, Fentanyl 25 micrograms/h transdermal patch, Fentanyl 50 micrograms/h transdermal patch, Oxycodone 5 mg prolonged-release tablets, Oxycodone 20 mg prolonged-release tablets, Oxycodone & Naloxone (5 mg/2.5 mg) prolonged-release tablets, Oxycodone & Naloxone (20 mg/10 mg) prolonged-release tablets, Hydromorphone 4 mg Prolonged Release tablets, Hydromorphone 8 mg Prolonged Release tablets, Morphine 10 mg prolonged-release tablets, Morphine 20 mg prolonged-release tablets, Tapentadol 50 mg prolonged-release tablets, Tapentadol 100 mg prolonged-release tablets, Buprenorphine 5 µg/h Transdermal Patch, Buprenorphine 15 µg/h Transdermal Patch, Buprenorphine 35 µg/h Transdermal Patch, VER-01, NA, Not Applicable, Oral solution, Prolonged-release tablet, Transdermal patch
Vertanical GmbH, Vertanical GmbH
Chronic non-specific low back pain, Back pain in between the lower edge of the ribs and the lower fold of the buttocks lasting for at least 3 months which has no specific identifiable cause, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
2012-003770-11: A multi-center, randomized parallel group pilot study to investigate the mechanism of action of tapentadol PR and oxycodone CR in subjects with osteoarthritis knee pain

Ongoing
2
60
Europe
Palexia Depot, OxyContin, Palexia Depot, OxyContin
C4Pain ApS, Grünenthal GmbH
Osteoarthritic Knee Pain.
 
 
ChiCTR2500097430: Study of human bioequivalence of Tapentadol Hydrochloride Prolonged-Release Tablets

Not yet recruiting
N/A
64
 
In the first cycle, all participants were fasted for at least 10 hours, and a blank blood sample was collected on the morning of each cycle of dosing, and 1 tablet of the test preparation or reference preparation (swallowed whole) was taken orally according to the random table of administration in the fasting state. The second cycle of the study was conducted after 7 days, and the dosing schedule of the second cycle was the same as that of the first cycle.; In the first cycle, all participants were fasted for at least 10 hours, and a blank blood sample was collected on the morning of each cycle of dosing, and 1 tablet of the test preparation or reference preparation (swallowed whole) was taken orally according to the random table of administration in the fasting state. The second cycle of the study was conducted after 7 days, and the dosing schedule of the second cycle was the same as that of the first cycle.
Second Affiliated Hospital of Guangzhou Medical University; Yichang Humanwell Pharmaceutical Co.,Ltd., Yichang Humanwell Pharmaceutical Co.,Ltd.
Severe chronic pain
 
 
Nerixia (nerindronic acid) / Abiogen, Grunenthal, Takeda
2021-006497-23: Corticosteroid medication in treatment of a sudden inflammation of the voice box among vocal professionals Kortisonilääkitys äkillisen kurkunpäätulehduksen hoidossa ääniammattilaisilla

Not yet recruiting
4
70
Europe
Prednisolon, Tablet, Prednisolon
Helsinki University Hospital, No
Laryngitis Kurkunpäätulehdus, Inflammation of the voice box Kurkunpäätulehdus, Diseases [C] - Ear, nose and throat diseases [C09]
 
 
2010-018904-94: EFFICACY AND SAFETY OF INTRAMUSCULAR NERIDRONATE IN OSTEOPOROTIC PATIENTS AFFECTED BY PARKINSON'S DISEASE EFFICACIA E SICUREZZA DEL NERIDRONATO INTRAMUSCOLARE NEL TRATTAMENTO DELL OSTEOPOROSI IN PAZIENTI PARKINSONIANI

Ongoing
3
60
Europe
Solution for injection, NERIXIA*IM EV 1F 25MG
FONDAZIONE SALVATORE MAUGERI - CLINICA DEL LAVORO E DELLA RIABILITAZIONE
Osteoporosis in patients affected by Parkinson's disaease at the stages 1-2-3-4 following Hoehn and Yahr criteria Osteoporosi in pazienti con m. di Parkinson stadi 1-2-3-4 sec Hoehn e Yahr, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
2014-001156-28: A randomized, double-blind, placebo controlled study to assess the safety and the efficacy of Neridronate ampoules 25 mg, after repeated intramuscular administrations, in patients with Complex Regional Pain Syndrome type I (CRPS-I) Studio randomizzato, in doppio cieco, controllato verso placebo, volto a valutare la sicurezza e l’efficacia di Neridronato 25 mg fiale, dopo ripetute somministrazioni intramuscolari, in pazienti con sindrome da dolore regionale complesso di tipo I (CRPS-I)

Ongoing
3
90
Europe
NERIXIA Soluzione iniettabile 25 mg, Solution for injection, NERIXIA Soluzione iniettabile 25 mg
Abiogen Pharma SpA, Abiogen Pharma SpA
Complex Regional Pain Syndrome type I (CRPS-I) Algodistrofia, Complex Regional Pain Syndrome type I (CRPS-I) Algodistrofia, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
2018-003505-26: Clinical trial to evaluate the efficacy, safety and tolerability of Neridronate versus Placebo in patients with transient osteoporosis of the hip. Studio clinico per valutare l'efficacia, la sicurezza e la tollerabilità del Neridronato verso il Placebo in pazienti con osteoporosi transitoria dell'anca.

Ongoing
3
60
Europe
Nerixia, [035268022], Concentrate for solution for infusion, NERIXIA - 100 MG CONCENTRATO PER SOLUZIONE PER INFUSIONE 2 FIALE
ABIOGEN PHARMA S.P.A.
Transient osteoporosis of the hip. Osteoporosi transitoria dell'anca., Transient osteoporosis of the hip. Osteoporosi transitoria dell'anca., Diseases [C] - Musculoskeletal Diseases [C05]
 
 
Revascor (rexlemestrocel-L) / Mesoblast, Grunenthal
2012-001818-42: A clinical trial of allogeneic mesenchymal precursor cells (MPCs) in the treatment of heart failure.

Ongoing
3
1165
Europe, RoW
Rexlemestrocel-L (CEP-41750), CEP-41750, Suspension for injection
Teva Branded Pharmaceutical Products R&D, Inc., Teva Branded Pharmaceutical Products R&D, Inc.
Chronic Heart Failure, Heart failure, Diseases [C] - Cardiovascular Diseases [C14]
 
 
MSB-DR004, NCT06325566: Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back Pain

Recruiting
3
300
US
Rexlemestrocel-L + HA mixture, Saline
Mesoblast, Ltd.
Degenerative Disc Disease
10/26
10/27
NCT03079401: Mesoblast Stem Cell Therapy for Patients With Single Ventricle and Borderline Left Ventricle

Active, not recruiting
1/2
19
US
MPC; rexlemestrocel-L, Allogeneic Mesenchymal Precursor Cell
Boston Children's Hospital
Hypoplastic Left Heart Syndrome, Atrioventricular Canal
12/22
01/24
Nebido (testosterone undecanoate depot injection) / Grunenthal
ACTRN12606000315516: The Quality of Life Outcomes and the Pharmacokinetic and Pharmacodynamic Sequelae of Testosterone Undecanoate Injections compared with Testosterone Implants for Androgen Replacement Therapy in men with Classical Male Hypogonadism

Recruiting
4
40
 
Schering Pty Ltd, Schering Pty Ltd
Male hypogonadism
 
 
2011-004266-15: Male sex hormone therapy to young males with hormone deficiency: 2 years, double-bld, placebo controlled study Behandling med manligt könshormon av unga män med hormonbrist: 2 års, randomiserad, dubbel-blind, placebo kontrollerad studie

Ongoing
4
160
Europe
testosterone undecanoate, Injection, Nebido
RMC, Skåne University Hospital, University Hospital of North Norway, Lund University, University Hospital of North Norway
Target population: Male hypogonadism (testosterone deficiency) As end points Bone mineralisation Body composition Markers of insulin sensitivity and cardiovascular disease Lipid profile Hemoglobin concentration amd hematocrit Studiepopulation: Manlig hypogonadism (testosteronbrist) Utfallsparametrar Bentäthet Kroppssammansättning Markörer för insulinkänslighet och kardiovaskulär funktion Lipid profil Hemoglobin/hematokrit, Men with sex hormone deficiency. Bone mineralisation Body composition Markers of insulin action and of cardiovascular disease Blood lipids Red blood cells Män med könshormonbrist Bentäthet Kroppssammansättning Insulinkänslighet och hjärt-kärl funktion Blodfetter Mängd röda blodkroppar, Diseases [C] - Hormonal diseases [C19]
 
 
2014-005179-10: A clinical trial for the effects of testosterone replacement therapy in male patients with hypogonadism on arterial function markers

Ongoing
4
24
Europe
Solution for injection, NEBIDO
Charalampos Vlachopoulos, Bayer Hellas ABEE
Male patients with hypogonadism, Male patients diagnosed with insufficient levels of testosterone, Diseases [C] - Cardiovascular Diseases [C14]
 
 
2011-006114-14: Effects of tesstosterone( male hormone) on glucose control and cardiovascular risk factors in men with type 2 diabetes

Ongoing
4
80
Europe
Nebido, not applicable, Nebido, Nebido
Research and Development department, Barnsley Research & Development
HypogonadismType 2 DiabetesCardiovascular risk
 
 
2012-000291-42: Effect of treatment with testosterone in diabetic patients (Type 1) with hypogonadism. Efecto del tratamiento con testosterona en pacientes diabéticos (tipo 1)con hipogonadismo.

Ongoing
4
28
Europe
Testosterone undecaonat, Reandron, REANDRON, REANDRON
Consorci Mar Parc de Salut de Barcelona (Parc de Salut Mar), Consorci Mar Parc de Salut de Barcelona (Parc de Salut Mar)
Diabetes Mellitus Type 1 (DM-1) and hipogonadotrophic hypogonadism Diabetes Mellitus Tipo I e hipogonadismo hipogonadotropo
 
 
2008-001459-23: Treatment of Testosterone deficiency in men with Sleep Apnoea Syndrome utilising Nebido therapy.

Ongoing
4
20
Europe
Nebido, Nebido
Nikolai Sleep Monitoring Clinic
Sleep ApnoeaHypogonadism- testosterone deficiency syndrome
 
 
2015-000502-19: Effects of sex hormones on serotonin synthesis and degradation measured with positron emission tomography Effekte von Sexualhormonen auf Serotoninsynthese und -Abbau, gemessen mit der Positronen-Emissions-Tomographie

Ongoing
4
92
Europe
Finasteride, Orgametril, Estradot, Estradiol hemihydrate, Estradiol, 12.352, Injection, Tablet, Transdermal patch, Transdermal gel, Nebido, Finasteride, Orgametril, Androcur, Cerazette, Decapeptyl, Estradot, Estrofem, Estrogel, Testogel
Medical University of Vienna, Department of Psychiatry and Psychotherapy, FWF
Gender Dysphoria (Female-to-male transsexuals and male-to-female transsexuals), A person who has a strong conviction of belonging to the opposite sex and whants to live and be accepted as a member of the opposite sex, Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
2018-002365-19: Testosterone in bariatric patients Testosteron behandling af mænd der undergår bariatrisk kirurgi.

Not yet recruiting
4
50
Europe
Nebido
Line Velling Magnussen, Hospital of Southwest Jutland, Odense University Hospital, Region of Southern Denmark
General aimTo investigate the effect and clinical relevance of testosterone therapy combined with exercise and diet counselling in hypogonadal men undergoing bariatric surgery.ObjectivesTo evaluate the effect of testosterone therapy combined with exercise and diet counselling on muscle strength, body composition, hormones, components of the metabolic syndrome, inflammation, sexual function, and quality of life after weight loss in obese, hypogonadal men undergoing bariatric surgery. -, - Kan man bibeholde muskelmassen og muskelstyrken under et vægttab foranlediget af gastric bypass ved at behandle mænd med nedsat testosteron i blodet med testosteron og livsstilsændringer, Not possible to specify
 
 
2017-001611-37: Studying the effects of intramuscular testosterone supplementation compared with placebo on liver fat content in obese men with low testosterone levels and type 2 diabetes (T2DM) or prediabetes followed by a subsequent open label phase to investigate metabolic long term effects.

Not yet recruiting
4
40
Europe
Testosterone undecanoate, G03BA03, Solution for injection, Nebido
Medical University Vienna, Gender Medicine Unit, Div. of Endocrinology, Dep of Medicine III, Medical University of Vienna, Bayer AG
hypogonadism, T2DM, prediabetes, overweight, obesity, low testosterone levels, high blood glucose levels, overweight and severe overweight, Diseases [C] - Hormonal diseases [C19]
 
 
2019-004349-34: Early mental response to hormonal treatment in transgender men Snabba mentala effekter av testosteronbehandling hos transseåualla kvinnor till män

Not yet recruiting
4
50
Europe
Solution for injection, Nebido
Karolinska University Hospital, Karolinska University Hospital
Transsexualism Transsexualism, Transsexualism Transsexualism, Psychiatry and Psychology [F] - Psychological processes [F02]
 
 
ChiCTR2000030594: Phase II / III clinical study on the efficacy and safety of recombinant human erythropoietin combined with retinoic acid and testosterone undecanoate in the treatment of anemia in patients with relatively low-risk myelodysplastic syndrome

Not yet recruiting
4
264
 
Recombinant human erythropoietin: 10000 IU subcutaneous injection once a day; retinoic acid: 20mg oral twice a day; testosterone undecanoate: 80mg oral twice a day ;Recombinant human erythropoietin: 10000 IU subcutaneous injection once a day ;Recombinant human erythropoietin: 10000 IU subcutaneous injection once a day; retinoic acid: 20mg oral twice a day; testosterone undecanoate: 80mg oral twice a day
The First Affiliated Hospital, College of Medicine, Zhejiang University; The First Affiliated Hospital, College of Medicine, Zhejiang University, Research funding
Myelodysplastic Syndrome
 
 
ChiCTR2000032845: Prospective, open-label, multicenter clinical study on the efficacy and safety of recombinant human erythropoietin combined with retinoic acid and testosterone undecanoate in the treatment of anemia in patients with low-risk myelodysplastic syndrome

Not yet recruiting
4
264
 
Recombinant human erythropoietin: 10000 IU subcutaneous injection once a day; retinoic acid: 20mg oral twice a day; testosterone undecanoate: 80mg oral twice a day ;Recombinant human erythropoietin: 10000 IU subcutaneous injection once a day
The First Affiliated Hospital of Zhejiang University Medical College; The First Affiliated Hospital, College of Medicine, Zhejiang University, Research funding
Myelodysplastic Syndrome
 
 
NCT04456296: A Study of the Effect of Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism

Completed
4
673
US
Aveed Injectable Product, Testosterone undecanoate, Fortesta, Testosterone gel, Testim
Endo Pharmaceuticals
Hypogonadism, Hypogonadism, Male, Hypogonadotropic Hypogonadism
07/23
07/23
Test2Func, NCT03851627: Effects of Testosterone Undecanoate vs Placebo on Intrahepatic Fat Content in Overweight/Obese Men With T2DM or Prediabetes and Hypogonadism

Recruiting
4
32
Europe
Testosterone Undecanoate, Nebido, Placebo, oily solution, Nebido like Placebo
Alexandra Kautzky-Willer, Bayer
Fatty Liver, Overweight/Obesity, Prediabetes/Type2 Diabetes Mellitus, Hypogonadism, Male
09/28
12/28
2006-004872-11: Role of testosterone and its metabolites on different physiological functions in subjects affected by gender identity disorde GID FtM transsexuals

Ongoing
3
15
Europe
Nebido, FEMARA*30CPR RIV 2,5MG, AVODART*30CPS 0,5MG, Nebido, FEMARA*30CPR RIV 2,5MG, AVODART*30CPS 0,5MG
AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
Maintenance of the characteristics and functions androgen-employee in FtM subjects after participation of RCS isteroannessiectomia.
 
 
2020-003012-27: Impact of testosterone on sexual functioning, urinary continence and oncological outcome following radical prostatectomy De invloed van testosterone op erecties, urinecontinentie en oncologische uitkomsten na radicale prostatectomy

Not yet recruiting
3
750
Europe
Testosterone undecanoate, Solution for injection, Nebido
Canisius Wilhelmina Ziekenhuis, To be determined
Late-onset hypogonadism Hypogonadisme, Low testosterone Verlaagd testosteron, Diseases [C] - Hormonal diseases [C19]
 
 
NCT04456530: Use of Testosterone to Prevent Post-Surgical Muscle Loss - Pilot Study

Enrolling by invitation
2/3
15
US
Aveed 750 MG in 3 ML IM Injection, Normal Saline 3 ML IM Injection
The Stone Research Foundation for Sports Medicine and Arthritis
Muscle Atrophy, Surgery, Knee Injuries and Disorders, Complication of Surgical Procedure, Trauma
12/21
06/22
NCT05964920: Does Human Skeletal Muscle Possess an Epigenetic Memory of Testosterone?

Recruiting
2/3
40
Europe
Saline, Placebo, Testosterone Undecanoate, Nebido, Grünenthal (Grünenthal Norway AS), Saline + Resistance exercise training, Placebo + Resistance exercise training, Testosterone Undecanoate + Resistance exercise training, Nebido, Grünenthal (Grünenthal Norway AS) + Resistance exercise training
Norwegian School of Sport Sciences, Oslo University Hospital
Healthy Aging, Age-Related Sarcopenia, Testosterone Deficiency
07/25
09/25
2012-002337-11: Hormone treatment of boys with absent or delayed puberty Hormonbehandling av pojkar med fördröjd eller utebliven pubertet

Ongoing
2
70
Europe
Solution for injection, Testoviron Depot® Soulution for injection i.m. 250mg/mL, Puregon 300 IE/0,36 ml, solution for injection, Nebido 1000 mg/4 ml injektionsvätska, lösning
Västra Götalandsregionen (VGR), Sahlgrenska Academy-Gothenburg University Institute, Västra Götalandregionen (VGR), Sahlgrenska Academy-Gothenburg University Institute
Delayed or absence of puberty Fördröjd eller utebliven pubertet, Young males with delayed or absence of puberty will be treated with testosterone replacement therapy Pojkar med fördröjd eller utebliven pubertet kommer att behandlas med testosterontillskott, Body processes [G] - Physiological processes [G07]
 
 
2007-005315-26: Sperm Suppression and Contraceptive Protection provived by Norethisterone Enantate (NET-EN) combined with Testosterone Undecanoate (TU) in healthy men.

 
2
110
Europe
Testosterone undecanoat, Noristerat, Nebido, Noristerat, Nebido
CONRAD, Eastern Virgina Medical School, CONRAD EASTERN VIRGINIA MEDICAL SCHOOL
The proposed study is designed to evaluate whether the combination of a progestin, norethisteroneenantate (NET-EN), and an androgen, testosterone undecanoate (TU), represents a safe and effectivemethod of male fertility regulation.
 
04/11
2010-021268-13: The Effects of Normalising Sex Hormone Levels in Obese Hypogonadal Men: A Prospective Randomized Comparator Controlled Parallel Arm Clinical Trial

Ongoing
2
90
Europe
Femara 2.5mg Tablets, Nebido 1000mg/4ml, solution for injection, Femara 2.5mg Tablets, Nebido 1000mg/4ml, solution for injection
University College Dublin
Obesity Related Male Hypogonadism
 
 
2018-002648-10: TestOsterone TreatmEnt in Relapsing Remitting Multiple Sclerosis Traitement de la SEP récurrente-rémittente (SEP-RR) par la testostérone

Not yet recruiting
2
80
Europe
Solution for injection, NEBIDO
Hôpitaux Universitaires de Strasbourg, DGOS, BAYER PHARMA AG, FHU Neurogenycs
Relapsing Remitting Multiple sclerosis Sclérose en Plaques Récurrente Rémittente, Multiple sclerosis Sclérose en Plaques, Diseases [C] - Nervous System Diseases [C10]
 
 
NCT04049331: Testosterone Replacement in Male Cancer Survivors with Fatigue and Low Testosterone

Recruiting
2
240
US
Testosterone Undecanoate 750 MG/3 ML Intramuscular Solution [AVEED], study drug, placebo
Seattle Institute for Biomedical and Clinical Research
Hypogonadism, Male, Fatigue Syndrome, Chronic
01/27
01/27
TOTEM-RRMS, NCT03910738: TOTEM RRMS : TestOsterone TreatmEnt on Neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis

Recruiting
2
40
Europe
Nebido® Testosterone Undecanoate 1000 Mg/4 mL Solution for Injection, Placebo 4 mL Solution for Injection, MRI, Assessment of impact of MS on cognition; quality of life; fatigue; anxiety/depression and work and activities, Assessment of disability
University Hospital, Strasbourg, France, Bayer, Fédération Hospitalo-Universitaire NEUROGENYCS, Grünenthal GmbH
Multiple Sclerosis, Relapsing-Remitting
12/27
12/27
T esters, NCT06393634: Comparing Direct and Indirect Detection Methods of Multiple Routes of Testosterone Administration

Completed
1
14
US
Testosterone injection, testosterone cipionate, enanthate,or propionate, Testosterone gel, testosterone transdermal, Testosterone Oral, testosterone undecanoate
Sports Medicine Research and Testing Laboratory
Healthy
11/24
11/24
ChiCTR1900024702: Clinical study for acupoint injection of chorionic gonadotropin in the treatment of late-onset hypogonadism in males

Not yet recruiting
N/A
60
 
Acupoint injection of HCG ;Intramuscular injection of HCG ;Oral testosterone undecanoate capsules
Guilin People's Hospital; Guilin People's Hospital, Scientific Research Project of Guangxi Medical and Health Self-financing(Z20190004)
Late-onset hypogonadism in males
 
 
ChiCTR2200062012: Acquired hypogonadism was treated with pulsed GnRH to reconstruct reproductive function

Not yet recruiting
N/A
120
 
Male patients treated with gonadotropin, including HCG preparation; In the HCG+HMG combined treatment period, HCG (2000u IM, 2-3 times a week) was given at the beginning of the method, and HMG(75-150u IM, 3 times a week) was added 3 months later according to the level of sex hormones, for 1 yea ;For both men and women, the same method can be used to pump subcutaneously at an interval of 90min with a single pulse initial dose of 5-10ug. If LH and/or FSH peak value ≤5Iu/L, increase by 5ug, the maximum dose is 25ug, and the course of treatment is 1 year ;Male should take testosterone undecanoate 40mg orally 3 days; Women received sequential estrogen progesterone therapy. ;Nothing
Second Affiliated Hospital of Army Military Medical University (Xinqiao Hospital) ; Second Affiliated Hospital of Army Military Medical University (Xinqiao Hospital), The subject is selected by the department
Acquired hypogonadism
 
 
EMRE, NCT05649605: Early Mental Response - The Study

Recruiting
N/A
70
Europe
Testosterone treatment, Nebido (3-oxandrostenderivate), testosterone undecanoate, Placebo treatment, Sodium chloride solution
Karolinska University Hospital
Gender Dysphoria, Gender Identity, Gender Issues
12/25
12/26
Versatis LE (lidocaine/diclofenac epolamine FDC patch) / Grunenthal
2016-002611-18: Lidocaine/diclofenac epolamine patch (GRT7019) Phase II proof-of-concept trial in patients with chronic pain due to knee osteoarthritis.

Ongoing
2
300
Europe
Lidocaine 700 mg / Diclofenac epolamine 182 mg Patch, GRT7019, Medicated plaster, Modified-release tablet, Gastro-resistant tablet, Versatis 5% medicated plaster, Diclo 75 SL - 1A Pharma, Pantoprazol-ratiopharm 20 mg
Grünenthal GmbH, Grünenthal GmbH
osteoarthritis, osteoarthritis, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
resiniferatoxin (GRT7039) / Grunenthal
2021-005046-15: Open-label trial to check the safety and tolerability of RTX-GRT7039 injections for pain associated with osteoarthritis of the knee.

Ongoing
3
715
Europe
RTX-GRT7039, Concentrate for solution for injection
Grünenthal GmbH, Grünenthal GmbH
Moderate to severe pain associated with Osteoarthritis of the knee, Pain due to osteoarthritis of the knee, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
2021-005029-26: Comparison of RTX-GRT7039 and placebo injections for pain associated with osteoarthritis of the knee.

Not yet recruiting
3
720
Europe, RoW
NA, Ropivacaina, RTX-GRT7039, Concentrate and solvent for solution for injection
Grünenthal GmbH, GRUNENTHAL GMBH, Grünenthal GmbH
Moderate to severe pain associated with osteoarthritis of the knee, Pain due to osteoarthritis of the knee, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
NCT05248386: Efficacy and Safety of RTX-GRT7039 in Adult Subjects With Knee Osteoarthritis

Completed
3
450
Europe, Canada, Japan, RoW
RTX-GRT7039, Placebo
Grünenthal GmbH
Osteoarthritis
11/24
11/24
NCT05449132 / 2021-005020-38: Comparison of a Single RTX-GRT7039 and Placebo Intra-articular Injection for Pain Associated With Osteoarthritis of the Knee

Completed
3
450
Europe, US
RTX-GRT7039, Placebo
Grünenthal GmbH, Grünenthal GmbH
Osteoarthritis
08/24
08/24
NCT05377489: Open-label Trial to Check the Safety and Tolerability of RTX-GRT7039 Injections for Pain Associated With Osteoarthritis of the Knee

Active, not recruiting
3
930
Europe, Japan, US, RoW
RTX-GRT7039
Grünenthal GmbH
Osteoarthritis
05/25
05/25
2017-004049-26: Lopain (MTX-071 / resiniferatoxin) Study to determine the safety and clinical effects of intra-articular injections of low doses of Lopain (MTX-071) in patients with chronic osteoarthritic knee joint pain

Ongoing
2
24
Europe
Lopain, MTX-071, Concentrate for solution for injection
Mestex, Mestex AG
chronic osteoarthritic knee-joint pain, Pain due to degenerative lesions of the knee joint, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
2018-000818-37: The pain reduction effects of different doses of Lopain (MTX-071) relative to placebo are evaluated in patients with chronic osteoarthritic knee joint pain. Porovnávanie efektu zníženia bolesti pri rôznych dávkach Lopainu (MTX-071) oproti placebu hodnoteného u pacientov s chronickou osteoartritídou kolenného kĺbu.

Ongoing
2
60
Europe, RoW
Lopain, MTX-071, Concentrate for solution for injection
Mestex AG, Mestex AG
chronic osteoarthritic knee joint pain, pain due to degenerative lesions of the knee joint, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
RTX-GRT7039 / Grunenthal
2021-005020-38: Comparison of a single RTX-GRT7039 and placebo intra-articular injection for pain associated with osteoarthritis of the knee. Demostrar la eficacia de una única inyección intraarticular de RTX-GRT7039 en comparación con el placebo para el dolor derivado de la gonartrosis

Ongoing
3
450
Europe
RTX-GRT7039, Concentrate for solution for injection
Grünenthal GmbH, Grünenthal GmbH
Moderate to severe pain associated with osteoarthritis of the knee Dolor de intensidad moderada a grave causado por una gonartrosis, Pain due to osteoarthritis of the knee Dolor asociado a una gonartrosis, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
cebranopadol (TRN-228) / Tris Pharma
ALLEVIATE-2, NCT06423703: A Study of Cebranopadol for the Treatment of Acute Pain After Bunionectomy

Recruiting
3
240
US
Cebranopadol, Oxycodone IR, Placebo
Tris Pharma, Inc.
Acute Pain
02/25
03/25
ALLEVIATE-1, NCT06545097: A Study of Cebranopadol for the Treatment of Acute Pain After Abdominoplasty

Active, not recruiting
3
300
US
Cebranopadol, Placebo
Tris Pharma, Inc.
Acute Pain
12/24
02/25
NCT05491785: Cebranopadol Effects on Ventilatory Drive, Central Nervous System (CNS) and Pain.

Completed
1
30
Europe
Cebranopadol 600 µg, Experimental, Cebranopadol 800 µg, Cebranopadol 1000 µg, Oxycodone 30 mg, Active Comparator, Oxycodone 60 mg, Placebo, Placebo comparator
Tris Pharma, Inc.
Pain
03/23
01/24
NCT06453265: A Study to Assess the Abuse Potential of Intranasal Cebranopadol

Active, not recruiting
1
45
US
Cebranopadol- 600 ug, Cebranopadol- 800ug, Cebranopadol- 1000ug, Treatment A:, Treatment B, Treatment C, Qualification
Tris Pharma, Inc.
Abuse, Drug
11/24
03/25
Nucynta (tapentadol) / Collegium Pharma, Grunenthal
2010-023175-26: Influence of Tapentadol on endogenous modulation of pain in chronic neuropathic pain patients and healthy volunteers

Ongoing
4
24
Europe
Tapentadol, morphine, Tapentadol, morphine, Tapentadol, morphine
Leiden University Medical Center
Chronic pain patients/ mhealthy volunteers
 
 
2015-005259-28: A study on the efefct of the analgesic tapentadol on pain scores in patients with low back pain

Ongoing
4
40
Europe
Tapentadol, N02AX06, Tablet, Palexia
LUMC, LUMC, Grunenthal
Low back pain, pain in the back, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
2015-005258-37: Effect of treatment with the painkiller tapentadol on pain in patients with fibromyalgia

Ongoing
4
40
Europe
Tapenatdol, N02AX06, Tablet, Pallexia
LUMC, LUMC, Grunenthal GmbH
Fibromyalgia, Fibromyalgia, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
2018-003515-22: Breathing effects of two opioid pain killers in healthy volunteers

Not yet recruiting
4
24
Europe
Tapentadol, Oxycodone, N02AX06, RVG110728, Tablet, Pallexia, Oxycodone
Leiden University Medical Center, Grunenthal
Chronic pain, Chronic pain, Body processes [G] - Physiological processes [G07]
 
 
2018-004804-21: The prevention of chronic postoperative pain.

Not yet recruiting
4
540
Europe
Tapentadol, Tablet, Tapentadol
Leiden University Medical Center, Grunenthal
Chronic pain after inguinal hernia surgery and knee replacement surgery., Chronic pain after surgery., Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03]
 
 
NCT06269770: Tapentadol vs Tramadol in Total Knee Arthroplasty

Recruiting
4
96
Europe
Tapentadol, Tramadol
University of Thessaly
Total Knee Replacement, Post-operative Pain, Chronic Pain
05/25
06/25
2006-004514-40: A Randomized, Double-Blind, Active- And Placebo-Controlled, Parallel Group, Multicenter Study To Evaluate The Efficacy And Safety of Multiple Doses of CG5503 Immediate Release Formulation In Subjects Awaiting Primary Joint Replacement Surgery for End-Stage Joint Disease

Ongoing
3
100
Europe
CG5503; R331333, OxyNorm, CG5503; R331333, n.a., OxyNorm 5, 10, 20 mg, OxyNorm 5, 10, 20 mg
Johnson & Johnson Pharamceutical Research & Development, L.L.C.
Pain
 
 
ChiCTR2300069799: Efficacy and Safety of Tapentadol Hydrochloride Tablets in Subjects with Moderate to Severe Pain after Orthopedic Surgery: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Phase III Study

Not yet recruiting
3
286
 
Oral administration Tapentadol Hydrochloride tablets ;Oral administration Oxycodone hydrochloride capsules
The Third Xiangya Hospital of Central South University; Third Xiangya Hospital of Central South University, Jiangsu Enhua Pharmaceutical Co., LTD., National Natural Science Foundation of China, Hunan Natural Science Foundation, Self-funded
Postoperative pain
 
 
2019-000755-14: Trial in healthy subjects to investigate the effect of analgesic drug on pain processing observed by non-invasive neurophysiological measurements of human spinal cord and brainstem activity. Studio su soggetti sani volto ad indagare gli effetti di farmaci analgesici sulla elaborazione del dolore mediante misure neurofisiologiche del'attività del midollo del midollo spinale e del tronco dell'encefalo

Ongoing
2
56
Europe
pregabalin, lacosamide, tapentadol, [N03AX16], [N/A], [N02AX06], Capsule, hard, Film-coated tablet, Tablet, LYRICA - 75 MG CAPSULA RIGIDA - USO ORALE 100 CAPSULE IN BLISTER IN UNITA' SEPARABILI PERFORATO (PVC/ALU), VIMPAT - 100 MG - COMPRESSE RIVESTITE CON FILM - USO ORALE - BLISTER (PVC/PVDC/ALU) 14 COMPRESSE, PALEXIA - 50 MG COMPRESSE RIVESTITE CON FILM 10 COMPRESSE IN BLISTER PVC/PVDC/AL
UMBERTO I - POLICLINICO DI ROMA, Teva Pharmaceutical Industries LTD, Innovative Medicines Initiative 2 (IMI2) Joint Undertaking under grant agreement, Eli Lilly and Company LTD, Esteve Pharmaceuticals SA, Grünenthal GmbH
Healthy volunteers (intended indication: pain) soggetti sani (indicazione: dolore), Healthy volunteers (intended indication: pain) soggetti sani (indicazione: dolore), Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03]
 
 
2019-000942-36: The effects of lacosamide, pregabalin and tapentadol on biomarkers of peripheral pain processing

Not yet recruiting
2
60
Europe
lacosamide, Pregabalin, Tapentadol, [N02AX06], [N/A], [N03AX16], Tablet, Capsule, Vimpat 100 mg film coated tablets, Lyrica 75 mg hard capsules, Palexia 50 mg film-coated tablets
Aarhus University, UMBERTO I - POLICLINICO DI ROMA, Innovative Medicines Initiative 2 (IMI2) Joint Undertaking under grant agreement, Eli Lilly and Company LTD, Esteve Pharmaceuticals SA, Grünenthal GmbH, Teva Pharmaceutical Industries LTD
Healthy volunteers (intended indication: pain), Study in healthy volunteers to examine drug effects on biomarkers in experimental pain, Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03]
 
 
2019-001204-37: The effects of lacosamide, pregabalin and tapentadol on biomarkers of pain processing

Not yet recruiting
2
56
Europe
lacosamide, pregabalin, tapentadol, [N02AX06], [N03AX16], [N/A], Film-coated tablet, Capsule, Tablet, Vimpat 100mg film coated tablets, Lyrica 75 mg hard capsules, Palexia 50 mg film-coated tablets
Institute of Neuroscience (IoNS), Université catholique de Louvain, UMBERTO I - POLICLINICO DI ROMA, Innovative Medicines Initiative 2 (IMI2) Joint Undertaking under Grant Agreement, Eli Lilly and Company LTD, Esteve Pharmaceuticals SA, Grünenthal GmBH, Teva Pharmaceutical Industries LTD
Healthy subjects (intended indication: pain), Study in healthy subjects to examine drug effects on biomarkers in experimental pain, Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03]
 
 
Qutenza (capsaicin) / Grunenthal, LTS Lohmann Therapy Systems
2012-002406-46: Comparison of different Capsaicin doses and their effects on nerve fibres in the skin Vergleich unterschiedlicher Capsaicin Dosierungen und ihr Einfluss auf die Nervenfasern in der Haut

Ongoing
4
12
Europe
Qutenza, Capsaicin 0,05% Ointment, N01BX04, Qutenza, Qutenza
Medizinische Universität Wien, Universitätsklinik für Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie, Medizinische Universität Wien
Impact of Capsaicin on epidermal nerve fibres Einfluss von Capsaicin auf epidermale Nervenfasern
 
 
2013-002546-36: Painthresholds under high-dose topical Capsaicin

Ongoing
4
20
Europe
Qutenza, Qutenza, Qutenza
Medizinische Universität Wien, Universitätsklinik für Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie, Medizinische Universität Wien, Universitätsklinik für Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie
Pain
 
 
2017-004746-17: Treatment of nerve pain in patients with diabetes with a capsaicin (chilli pepper) patch (skin plaster).

Ongoing
4
50
Europe
Qutenza (Capsaicin) 8 % patch, Cutaneous patch, Qutenza (Capsaicin) 8 % patch
Joint Research Compliance Office, Imperial College London and Imperial College Healthcare NHS Trust, Diabetes UK
Diabetic painful neuropathy, Nerve damage with pain in patients with diabetes, Diseases [C] - Nervous System Diseases [C10]
 
 
2018-003617-17: Localized neuropathic pain: topical treatment versus systemic treatment

Not yet recruiting
4
591
Europe
Cutaneous patch, Capsule, hard, Lidocaïne Grünenthal 700 mg pleister (Versatis), Capsaicine (Qutenza) 179 mg huidpleister, Pregabaline (Lyrica) 75 mg harde capsules
Antwerp University Hospital (UZA), Belgian Health Care Knowledge Center (KCE)
Patients suffering from localized neuropathic pain (LNP), Patients suffering from localized neuropathic pain (LNP), Diseases [C] - Nervous System Diseases [C10]
 
 
2020-001022-57: Treatment with small Qutenza patches over painful trigger points in scars after operation: A blinded study using placebo paths versus active Qutenza patch

Not yet recruiting
4
26
Europe
Qutenza 179 mg cutaneous patch, EMEA/H/C/00909, Cutaneous patch, Qutenza 179 mg kutanplaster
Wojciech Zbigniew Pawlak
Post-operative neuropathic pain, Pain after nerve damage, Diseases [C] - Nervous System Diseases [C10]
 
 
CADOR, NCT06444919: Capsaicin in Digital Osteoarthritis Versus Control

Recruiting
4
120
Europe
Capsaicin 179 Mg Cutaneous Patch, QUTENZA, Capsaicine low dose 0.04 %, control treatment
University Hospital, Clermont-Ferrand, Grünenthal GmbH
Osteoarthritis Hand, Neuropathic Pain
01/28
01/28
2018-003559-39: multicentric Study , open, randomized, comparing the topical treatment by patch of capsaïcine with 8 % ( Qutenza) to the oral prégabaline treatment in the early treatment of the neuropathic pains after a primary surgery for breast cancer ( CAPTRANE) Etude multicentrique, ouverte, randomisée, comparant le traitement topique par patch de capsaïcine à 8% (Qutenza) à la prégabaline per os dans le traitement précoce des douleurs neuropathiques après une chirurgie primaire pour cancer du sein (CAPTRANE)

Not yet recruiting
3
772
Europe
Cutaneous patch, Capsule, QUTENZA, PREGABALINE
INSTITUT DE CANCEROLOGIE DE L'OUEST, GRUNENTHAL
men and /or women older than 18 years with breast cancer for which a surgical operation was realized. homme et/ou femme de plus de 18 ans, atteint d’un cancer du sein pour lequel une intervention chirurgicale a été réalisée., men and /or women older than 18 years with breast cancer for which a surgical operation was realized. homme et/ou femme de plus de 18 ans, atteint d’un cancer du sein pour lequel une intervention chirurgicale a été réalisée., Diseases [C] - Cancer [C04]
 
 
2021-001409-64: A multi site clinical trial to evaluate the efficacy and safety of Qutenza® in subjects with post-surgical neuropathic pain Un ensayo clínico en varios centros para evaluar la eficacia y seguridad de Qutenza® en pacientes con dolor neuropático posquirúrgico

Not yet recruiting
3
510
Europe
Capsaicin, Cutaneous patch, Qutenza
Averitas Pharma, Inc., Averitas Pharma, Inc.
Post-surgical neuropathic pain (PSNP) Dolor neuropático posquirúrgico (DNPQ), Post-surgical neuropathic pain (PSNP) Dolor neuropático posquirúrgico (DNPQ), Body processes [G] - Physiological processes [G07]
 
 
CAPTRANE, NCT03794388: Evaluation in the Treatment of Neuropathic Pain Post Breast Surgery

Completed
3
140
Europe
Capsaicin, qutenza EU/1/09/524/001, Pregabalin, Lyrica
Institut Cancerologie de l'Ouest, Grünenthal GmbH
Breast Cancer Patient
11/22
11/22
NCT04967664 / 2021-001409-64: Comparison of Qutenza (8% Capsaicin) With a Low-dose Capsaicin for Treatment of Nerve Pain After Surgery

Active, not recruiting
3
409
Europe, US
Qutenza (capsaicin) 8% topical system, capsaicin 0.04% topical system
Averitas Pharma, Inc., Averitas Pharma, Inc.
Post Surgical Neuropathic Pain
03/25
08/25
CAPSAPED, NCT05997979: Analgesic Effectiveness of Capsaicin 8% Cutaneous Patch in Children

Recruiting
3
46
Europe
Capsaicin 8% patch, QUTENZA®, Hydrocolloid dressing, COMFEEL PLUS TRANSPARENT
University Hospital, Brest
Neuropathic Pain, Chronic Pain
04/26
04/26
CAPSACOX, NCT06023706: Study Evaluating the Analgesic Efficacy of Capsaicin 8% Patches in Chronic Coccygodynia.

Recruiting
3
188
Europe
Capsaicin 179 Mg Cutaneous Patch, qutenza, Capsaicin low concentration patch (capsaicin 0,04%, 3,2 mg/cm2)
Nantes University Hospital
Coccyx Disorder, Neuropathic Pain, Coccygodynia
01/27
06/27
CAPNEUCHIM, NCT05840562: Capsaicin 179 mg Patch Versus Oral Duloxetine in Patients With Chemotherapy-induced Peripheral Neuropathy

Recruiting
3
274
Europe
Capsaicin, Qutenza, Duloxetine, Cymbalta
Institut Cancerologie de l'Ouest, Grünenthal GmbH
Chemotherapy-induced Peripheral Neuropathy
03/27
03/27
2020-003965-21: Phase II Randomized Controlled Study Aiming to Evaluate the Interest of Qutenza in Patients With ORL Cancer in Remission and With Sequellae Neuropathic Pain. Phase II randomisée comparative visant à évaluer l’intérêt du Qutenza dans la prise en charge de patients en rémission de cancer ORL et présentant des douleurs neuropathiques séquellaires.

Not yet recruiting
2
130
Europe
Cutaneous patch, Oral solution, Qutenza®, Laroxyl®
INSTITUT CLAUDIUS REGAUD, DGOS
Head and neck cancer Cancer ORL, Head and neck cancer Cancer ORL, Diseases [C] - Cancer [C04]
 
 
NCT03464292: Spinal and Supra-Spinal Pain Mechanisms in Patients With Fibromyalgia

Completed
2
55
US
Capsaicin Patch 8% or 0.1% Capsaicin Cream, Qutenza, Capsaicin No-Fuss, Vehicle Patch
University of Florida
Fibromyalgia, Pain
07/23
12/23
SerCaBot, NCT06807164: Serratus Plane Block (SPB) Versus Capsaïcine Versus Botox-A for Chronic Neuropathic Pain in Post-mastectomy Syndrome

Recruiting
2
123
Europe
Capsaicin 8% Patch, Qutenza®, Serratus Plane Block, SPB, Botulinum Toxin A, Botox-A, Botox
Centre Oscar Lambret, Ligue contre le cancer, France, Santelys Association, CTD-CNO, Caen
Post-Mastectomy Neuropathic Pain Syndrome
08/27
12/27
TEC-ORL, NCT04704453 / 2020-003965-21: Study to Evaluate the Interest of Qutenza in Patients With Head and Neck Cancer in Remission and With Sequelae Neuropathic Pain.

Active, not recruiting
2
13
Europe
Capsaïcin patch (Qutenza®), Amitriptyline (Laroxyl®)
Institut Claudius Regaud, DGOS
Head and Neck Cancer
01/26
01/26
NCT06744816: Exploring the Benefit of Topical Capsaicin in Treating Pain From Chemo-induced Peripheral Neuropathy: a Longitudinal Single Center Pilot Study

Not yet recruiting
1
20
US
Qutenza Patch
M.D. Anderson Cancer Center, Averitas Pharma, Inc.
Peripheral Neuropathy Due to Chemotherapy
11/25
11/27
NCT06197529: Is Nociceptive Processing Evoked by Heat Homeostatically Regulated: A Contact-heat Evoked Potentials Study

Completed
N/A
18
Europe
Homeostatic Plasticity, Topical alone (Capsaicin 8% Patch), Qutenza Capsaicin (8%), Placebo Patch, Homeostatic Plasticity (Sham)
Aalborg University
Healthy
03/24
03/24
ALGOS, NCT05726929: Algology in Oncology Osteopathic Support

Completed
N/A
12
Europe
Osteopathic treatment, Capsaicin QUTENZA Patch (TAU)
Institut Toulousain d'Ostéopathie, Institut Claudius Regaud
Breast Cancer, Neuropathic Pain
12/24
12/24
CAPSACOXp, NCT05983263: Analgesic Efficacy of Capsaicin 8% Patch (QUTENZA®) in Coccygodygnia

Not yet recruiting
N/A
106
NA
Capsaicin, Capsaicin 8% patch
Nantes University Hospital
Coccyx Disorder
12/23
12/23
QULOX, NCT05560516: Qutenza Versus Duloxetine in Chemotherapy-induced Peripheral Neuropathy (CIPN)

Recruiting
N/A
102
Europe
Qutenza, Duloxetine
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Leiden University Medical Center, Reinier de Graaf
Qutenza, Duloxetine, Chemotherapy-induced Peripheral Neuropathy, CIPN - Chemotherapy-Induced Peripheral Neuropathy
12/24
12/25
NCT06495424: Observational Study to Evaluate the Efficacy of Sustained QUTENZA® Use in Painful Diabetic Peripheral Neuropathy

Not yet recruiting
N/A
150
NA
Capsaicin 8%
Averitas Pharma, Inc.
Peripheral Diabetic Neuropathy, Painful Diabetic Neuropathy
12/26
03/27
NCT06540456: Qutenza 8% Capsaicin Topical System for the Treatment of Neuropathic Axial Lower Back Pain and Lumbosacral Radiculopathy

Enrolling by invitation
N/A
50
US
Qutenza® 8% Capsaicin Topical System
Medical University of South Carolina, Averitas Pharma, Inc.
Lower Back Pain, Lumbosacral Radiculopathy
07/27
07/28
Palexia RP (tapentadol extended release) / Assertio, J&J, Grunenthal, Collegium Pharma
2017-000141-52: The effect of tapentadol and oxycodone on the human pain system Effekten af tapentadol og oxycodon på det humane smertenetværk

Ongoing
4
20
Europe
Palexia Depot, OxyContin, Modified-release tablet, Palexia Depot, OxyContin
Asbjørn Mohr Drewes, Grünenthal GmBH
Healthy volunteers - pain, Pain, Diseases [C] - Nervous System Diseases [C10]
 
 
2016-005082-31: Assessment of Tapentadol effects on patients with pain central sensitization using functional MRI Evaluación del efecto de tapentadol en pacientes con dolor por sensibilización central utilizando la resonancia magnética funcional (fMRI)

Ongoing
4
40
Europe
Palexia Retard, Palexia retard, Prolonged-release tablet, Palexia retard 50 mg, Palexia retard 100 mg, Palexia retard 150 mg, Palexia retard 200 mg, Palexia retard 250 mg
MRI Research Unit, Radiology Department. Hospital del Mar., Grunenthal Pharma S.A.
Patients suffering from pain due to knee osteoarthritis Pacientes con dolor por artrosis de rodilla, Patients suffering from pain due to knee osteoarthritis Pacientes con dolor por artrosis de rodilla, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
2017-001285-23: A comparison of pain relief and effects on respiration from tapentadol and oxycodone after surgical removal of the uterus.

Not yet recruiting
4
90
Europe
Tablet, Modified-release tablet, Capsule, hard, Palexia® 50 mg, Palexia depot®, OxyNorm®, OxyContin®
Oslo University Hospital, Oslo University Hospital
Pain after laparoscopic hysterectomy., Pain after surgical removal of the uterus using a minimal invasive surgical technique., Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03]
 
 
2009-017470-20: An open-label extension study for patients with severe chronic low back pain or severe chronic pain due to knee osteoarthritis who have completed any of the previous phase IIIb trials with tapentadol hydrochloride, KF5503/42, KF5503/44 or KF5503/45.

Ongoing
3
25
Europe
Tapentadol 50 mg film coated tablet, Tapentadol 50 mg prolonged release tablet, Tapentadol 100 mg prolonged release tablet, Tapentadol 150 mg prolonged release tablet, Tapentadol 200 mg prolonged release tablet, Tapentadol 250 mg prolonged release tablet, CG5503,
Laboratoires Grünenthal
Severe chronic pain
 
 
2022-001358-41: Clinical study to prove that treatment of chronic (non-specific) low back pain with VER-01, a cannabis based medicine, shows benefit compared to treatment with opioids

Not yet recruiting
3
350
Europe
Standardized oleoresin of Cannabis sativa L. folium cum flore, THC-chemotype, Tilidine and Naloxone (50 mg/4 mg) prolonged-release tablets, Tilidine and Naloxone (100 mg/8 mg) prolonged-release tablets, Tramadol 100 mg prolonged-release tablets, Tramadol 200 mg prolonged-release tablets, Fentanyl 12 micrograms/h transdermal patch, Fentanyl 25 micrograms/h transdermal patch, Fentanyl 50 micrograms/h transdermal patch, Oxycodone 5 mg prolonged-release tablets, Oxycodone 20 mg prolonged-release tablets, Oxycodone & Naloxone (5 mg/2.5 mg) prolonged-release tablets, Oxycodone & Naloxone (20 mg/10 mg) prolonged-release tablets, Hydromorphone 4 mg Prolonged Release tablets, Hydromorphone 8 mg Prolonged Release tablets, Morphine 10 mg prolonged-release tablets, Morphine 20 mg prolonged-release tablets, Tapentadol 50 mg prolonged-release tablets, Tapentadol 100 mg prolonged-release tablets, Buprenorphine 5 µg/h Transdermal Patch, Buprenorphine 15 µg/h Transdermal Patch, Buprenorphine 35 µg/h Transdermal Patch, VER-01, NA, Not Applicable, Oral solution, Prolonged-release tablet, Transdermal patch
Vertanical GmbH, Vertanical GmbH
Chronic non-specific low back pain, Back pain in between the lower edge of the ribs and the lower fold of the buttocks lasting for at least 3 months which has no specific identifiable cause, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
2012-003770-11: A multi-center, randomized parallel group pilot study to investigate the mechanism of action of tapentadol PR and oxycodone CR in subjects with osteoarthritis knee pain

Ongoing
2
60
Europe
Palexia Depot, OxyContin, Palexia Depot, OxyContin
C4Pain ApS, Grünenthal GmbH
Osteoarthritic Knee Pain.
 
 
ChiCTR2500097430: Study of human bioequivalence of Tapentadol Hydrochloride Prolonged-Release Tablets

Not yet recruiting
N/A
64
 
In the first cycle, all participants were fasted for at least 10 hours, and a blank blood sample was collected on the morning of each cycle of dosing, and 1 tablet of the test preparation or reference preparation (swallowed whole) was taken orally according to the random table of administration in the fasting state. The second cycle of the study was conducted after 7 days, and the dosing schedule of the second cycle was the same as that of the first cycle.; In the first cycle, all participants were fasted for at least 10 hours, and a blank blood sample was collected on the morning of each cycle of dosing, and 1 tablet of the test preparation or reference preparation (swallowed whole) was taken orally according to the random table of administration in the fasting state. The second cycle of the study was conducted after 7 days, and the dosing schedule of the second cycle was the same as that of the first cycle.
Second Affiliated Hospital of Guangzhou Medical University; Yichang Humanwell Pharmaceutical Co.,Ltd., Yichang Humanwell Pharmaceutical Co.,Ltd.
Severe chronic pain
 
 
Nerixia (nerindronic acid) / Abiogen, Grunenthal, Takeda
2021-006497-23: Corticosteroid medication in treatment of a sudden inflammation of the voice box among vocal professionals Kortisonilääkitys äkillisen kurkunpäätulehduksen hoidossa ääniammattilaisilla

Not yet recruiting
4
70
Europe
Prednisolon, Tablet, Prednisolon
Helsinki University Hospital, No
Laryngitis Kurkunpäätulehdus, Inflammation of the voice box Kurkunpäätulehdus, Diseases [C] - Ear, nose and throat diseases [C09]
 
 
2010-018904-94: EFFICACY AND SAFETY OF INTRAMUSCULAR NERIDRONATE IN OSTEOPOROTIC PATIENTS AFFECTED BY PARKINSON'S DISEASE EFFICACIA E SICUREZZA DEL NERIDRONATO INTRAMUSCOLARE NEL TRATTAMENTO DELL OSTEOPOROSI IN PAZIENTI PARKINSONIANI

Ongoing
3
60
Europe
Solution for injection, NERIXIA*IM EV 1F 25MG
FONDAZIONE SALVATORE MAUGERI - CLINICA DEL LAVORO E DELLA RIABILITAZIONE
Osteoporosis in patients affected by Parkinson's disaease at the stages 1-2-3-4 following Hoehn and Yahr criteria Osteoporosi in pazienti con m. di Parkinson stadi 1-2-3-4 sec Hoehn e Yahr, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
2014-001156-28: A randomized, double-blind, placebo controlled study to assess the safety and the efficacy of Neridronate ampoules 25 mg, after repeated intramuscular administrations, in patients with Complex Regional Pain Syndrome type I (CRPS-I) Studio randomizzato, in doppio cieco, controllato verso placebo, volto a valutare la sicurezza e l’efficacia di Neridronato 25 mg fiale, dopo ripetute somministrazioni intramuscolari, in pazienti con sindrome da dolore regionale complesso di tipo I (CRPS-I)

Ongoing
3
90
Europe
NERIXIA Soluzione iniettabile 25 mg, Solution for injection, NERIXIA Soluzione iniettabile 25 mg
Abiogen Pharma SpA, Abiogen Pharma SpA
Complex Regional Pain Syndrome type I (CRPS-I) Algodistrofia, Complex Regional Pain Syndrome type I (CRPS-I) Algodistrofia, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
2018-003505-26: Clinical trial to evaluate the efficacy, safety and tolerability of Neridronate versus Placebo in patients with transient osteoporosis of the hip. Studio clinico per valutare l'efficacia, la sicurezza e la tollerabilità del Neridronato verso il Placebo in pazienti con osteoporosi transitoria dell'anca.

Ongoing
3
60
Europe
Nerixia, [035268022], Concentrate for solution for infusion, NERIXIA - 100 MG CONCENTRATO PER SOLUZIONE PER INFUSIONE 2 FIALE
ABIOGEN PHARMA S.P.A.
Transient osteoporosis of the hip. Osteoporosi transitoria dell'anca., Transient osteoporosis of the hip. Osteoporosi transitoria dell'anca., Diseases [C] - Musculoskeletal Diseases [C05]
 
 
Revascor (rexlemestrocel-L) / Mesoblast, Grunenthal
2012-001818-42: A clinical trial of allogeneic mesenchymal precursor cells (MPCs) in the treatment of heart failure.

Ongoing
3
1165
Europe, RoW
Rexlemestrocel-L (CEP-41750), CEP-41750, Suspension for injection
Teva Branded Pharmaceutical Products R&D, Inc., Teva Branded Pharmaceutical Products R&D, Inc.
Chronic Heart Failure, Heart failure, Diseases [C] - Cardiovascular Diseases [C14]
 
 
MSB-DR004, NCT06325566: Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back Pain

Recruiting
3
300
US
Rexlemestrocel-L + HA mixture, Saline
Mesoblast, Ltd.
Degenerative Disc Disease
10/26
10/27
NCT03079401: Mesoblast Stem Cell Therapy for Patients With Single Ventricle and Borderline Left Ventricle

Active, not recruiting
1/2
19
US
MPC; rexlemestrocel-L, Allogeneic Mesenchymal Precursor Cell
Boston Children's Hospital
Hypoplastic Left Heart Syndrome, Atrioventricular Canal
12/22
01/24
Nebido (testosterone undecanoate depot injection) / Grunenthal
ACTRN12606000315516: The Quality of Life Outcomes and the Pharmacokinetic and Pharmacodynamic Sequelae of Testosterone Undecanoate Injections compared with Testosterone Implants for Androgen Replacement Therapy in men with Classical Male Hypogonadism

Recruiting
4
40
 
Schering Pty Ltd, Schering Pty Ltd
Male hypogonadism
 
 
2011-004266-15: Male sex hormone therapy to young males with hormone deficiency: 2 years, double-bld, placebo controlled study Behandling med manligt könshormon av unga män med hormonbrist: 2 års, randomiserad, dubbel-blind, placebo kontrollerad studie

Ongoing
4
160
Europe
testosterone undecanoate, Injection, Nebido
RMC, Skåne University Hospital, University Hospital of North Norway, Lund University, University Hospital of North Norway
Target population: Male hypogonadism (testosterone deficiency) As end points Bone mineralisation Body composition Markers of insulin sensitivity and cardiovascular disease Lipid profile Hemoglobin concentration amd hematocrit Studiepopulation: Manlig hypogonadism (testosteronbrist) Utfallsparametrar Bentäthet Kroppssammansättning Markörer för insulinkänslighet och kardiovaskulär funktion Lipid profil Hemoglobin/hematokrit, Men with sex hormone deficiency. Bone mineralisation Body composition Markers of insulin action and of cardiovascular disease Blood lipids Red blood cells Män med könshormonbrist Bentäthet Kroppssammansättning Insulinkänslighet och hjärt-kärl funktion Blodfetter Mängd röda blodkroppar, Diseases [C] - Hormonal diseases [C19]
 
 
2014-005179-10: A clinical trial for the effects of testosterone replacement therapy in male patients with hypogonadism on arterial function markers

Ongoing
4
24
Europe
Solution for injection, NEBIDO
Charalampos Vlachopoulos, Bayer Hellas ABEE
Male patients with hypogonadism, Male patients diagnosed with insufficient levels of testosterone, Diseases [C] - Cardiovascular Diseases [C14]
 
 
2011-006114-14: Effects of tesstosterone( male hormone) on glucose control and cardiovascular risk factors in men with type 2 diabetes

Ongoing
4
80
Europe
Nebido, not applicable, Nebido, Nebido
Research and Development department, Barnsley Research & Development
HypogonadismType 2 DiabetesCardiovascular risk
 
 
2012-000291-42: Effect of treatment with testosterone in diabetic patients (Type 1) with hypogonadism. Efecto del tratamiento con testosterona en pacientes diabéticos (tipo 1)con hipogonadismo.

Ongoing
4
28
Europe
Testosterone undecaonat, Reandron, REANDRON, REANDRON
Consorci Mar Parc de Salut de Barcelona (Parc de Salut Mar), Consorci Mar Parc de Salut de Barcelona (Parc de Salut Mar)
Diabetes Mellitus Type 1 (DM-1) and hipogonadotrophic hypogonadism Diabetes Mellitus Tipo I e hipogonadismo hipogonadotropo
 
 
2008-001459-23: Treatment of Testosterone deficiency in men with Sleep Apnoea Syndrome utilising Nebido therapy.

Ongoing
4
20
Europe
Nebido, Nebido
Nikolai Sleep Monitoring Clinic
Sleep ApnoeaHypogonadism- testosterone deficiency syndrome
 
 
2015-000502-19: Effects of sex hormones on serotonin synthesis and degradation measured with positron emission tomography Effekte von Sexualhormonen auf Serotoninsynthese und -Abbau, gemessen mit der Positronen-Emissions-Tomographie

Ongoing
4
92
Europe
Finasteride, Orgametril, Estradot, Estradiol hemihydrate, Estradiol, 12.352, Injection, Tablet, Transdermal patch, Transdermal gel, Nebido, Finasteride, Orgametril, Androcur, Cerazette, Decapeptyl, Estradot, Estrofem, Estrogel, Testogel
Medical University of Vienna, Department of Psychiatry and Psychotherapy, FWF
Gender Dysphoria (Female-to-male transsexuals and male-to-female transsexuals), A person who has a strong conviction of belonging to the opposite sex and whants to live and be accepted as a member of the opposite sex, Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
2018-002365-19: Testosterone in bariatric patients Testosteron behandling af mænd der undergår bariatrisk kirurgi.

Not yet recruiting
4
50
Europe
Nebido
Line Velling Magnussen, Hospital of Southwest Jutland, Odense University Hospital, Region of Southern Denmark
General aimTo investigate the effect and clinical relevance of testosterone therapy combined with exercise and diet counselling in hypogonadal men undergoing bariatric surgery.ObjectivesTo evaluate the effect of testosterone therapy combined with exercise and diet counselling on muscle strength, body composition, hormones, components of the metabolic syndrome, inflammation, sexual function, and quality of life after weight loss in obese, hypogonadal men undergoing bariatric surgery. -, - Kan man bibeholde muskelmassen og muskelstyrken under et vægttab foranlediget af gastric bypass ved at behandle mænd med nedsat testosteron i blodet med testosteron og livsstilsændringer, Not possible to specify
 
 
2017-001611-37: Studying the effects of intramuscular testosterone supplementation compared with placebo on liver fat content in obese men with low testosterone levels and type 2 diabetes (T2DM) or prediabetes followed by a subsequent open label phase to investigate metabolic long term effects.

Not yet recruiting
4
40
Europe
Testosterone undecanoate, G03BA03, Solution for injection, Nebido
Medical University Vienna, Gender Medicine Unit, Div. of Endocrinology, Dep of Medicine III, Medical University of Vienna, Bayer AG
hypogonadism, T2DM, prediabetes, overweight, obesity, low testosterone levels, high blood glucose levels, overweight and severe overweight, Diseases [C] - Hormonal diseases [C19]
 
 
2019-004349-34: Early mental response to hormonal treatment in transgender men Snabba mentala effekter av testosteronbehandling hos transseåualla kvinnor till män

Not yet recruiting
4
50
Europe
Solution for injection, Nebido
Karolinska University Hospital, Karolinska University Hospital
Transsexualism Transsexualism, Transsexualism Transsexualism, Psychiatry and Psychology [F] - Psychological processes [F02]
 
 
ChiCTR2000030594: Phase II / III clinical study on the efficacy and safety of recombinant human erythropoietin combined with retinoic acid and testosterone undecanoate in the treatment of anemia in patients with relatively low-risk myelodysplastic syndrome

Not yet recruiting
4
264
 
Recombinant human erythropoietin: 10000 IU subcutaneous injection once a day; retinoic acid: 20mg oral twice a day; testosterone undecanoate: 80mg oral twice a day ;Recombinant human erythropoietin: 10000 IU subcutaneous injection once a day ;Recombinant human erythropoietin: 10000 IU subcutaneous injection once a day; retinoic acid: 20mg oral twice a day; testosterone undecanoate: 80mg oral twice a day
The First Affiliated Hospital, College of Medicine, Zhejiang University; The First Affiliated Hospital, College of Medicine, Zhejiang University, Research funding
Myelodysplastic Syndrome
 
 
ChiCTR2000032845: Prospective, open-label, multicenter clinical study on the efficacy and safety of recombinant human erythropoietin combined with retinoic acid and testosterone undecanoate in the treatment of anemia in patients with low-risk myelodysplastic syndrome

Not yet recruiting
4
264
 
Recombinant human erythropoietin: 10000 IU subcutaneous injection once a day; retinoic acid: 20mg oral twice a day; testosterone undecanoate: 80mg oral twice a day ;Recombinant human erythropoietin: 10000 IU subcutaneous injection once a day
The First Affiliated Hospital of Zhejiang University Medical College; The First Affiliated Hospital, College of Medicine, Zhejiang University, Research funding
Myelodysplastic Syndrome
 
 
NCT04456296: A Study of the Effect of Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism

Completed
4
673
US
Aveed Injectable Product, Testosterone undecanoate, Fortesta, Testosterone gel, Testim
Endo Pharmaceuticals
Hypogonadism, Hypogonadism, Male, Hypogonadotropic Hypogonadism
07/23
07/23
Test2Func, NCT03851627: Effects of Testosterone Undecanoate vs Placebo on Intrahepatic Fat Content in Overweight/Obese Men With T2DM or Prediabetes and Hypogonadism

Recruiting
4
32
Europe
Testosterone Undecanoate, Nebido, Placebo, oily solution, Nebido like Placebo
Alexandra Kautzky-Willer, Bayer
Fatty Liver, Overweight/Obesity, Prediabetes/Type2 Diabetes Mellitus, Hypogonadism, Male
09/28
12/28
2006-004872-11: Role of testosterone and its metabolites on different physiological functions in subjects affected by gender identity disorde GID FtM transsexuals

Ongoing
3
15
Europe
Nebido, FEMARA*30CPR RIV 2,5MG, AVODART*30CPS 0,5MG, Nebido, FEMARA*30CPR RIV 2,5MG, AVODART*30CPS 0,5MG
AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
Maintenance of the characteristics and functions androgen-employee in FtM subjects after participation of RCS isteroannessiectomia.
 
 
2020-003012-27: Impact of testosterone on sexual functioning, urinary continence and oncological outcome following radical prostatectomy De invloed van testosterone op erecties, urinecontinentie en oncologische uitkomsten na radicale prostatectomy

Not yet recruiting
3
750
Europe
Testosterone undecanoate, Solution for injection, Nebido
Canisius Wilhelmina Ziekenhuis, To be determined
Late-onset hypogonadism Hypogonadisme, Low testosterone Verlaagd testosteron, Diseases [C] - Hormonal diseases [C19]
 
 
NCT04456530: Use of Testosterone to Prevent Post-Surgical Muscle Loss - Pilot Study

Enrolling by invitation
2/3
15
US
Aveed 750 MG in 3 ML IM Injection, Normal Saline 3 ML IM Injection
The Stone Research Foundation for Sports Medicine and Arthritis
Muscle Atrophy, Surgery, Knee Injuries and Disorders, Complication of Surgical Procedure, Trauma
12/21
06/22
NCT05964920: Does Human Skeletal Muscle Possess an Epigenetic Memory of Testosterone?

Recruiting
2/3
40
Europe
Saline, Placebo, Testosterone Undecanoate, Nebido, Grünenthal (Grünenthal Norway AS), Saline + Resistance exercise training, Placebo + Resistance exercise training, Testosterone Undecanoate + Resistance exercise training, Nebido, Grünenthal (Grünenthal Norway AS) + Resistance exercise training
Norwegian School of Sport Sciences, Oslo University Hospital
Healthy Aging, Age-Related Sarcopenia, Testosterone Deficiency
07/25
09/25
2012-002337-11: Hormone treatment of boys with absent or delayed puberty Hormonbehandling av pojkar med fördröjd eller utebliven pubertet

Ongoing
2
70
Europe
Solution for injection, Testoviron Depot® Soulution for injection i.m. 250mg/mL, Puregon 300 IE/0,36 ml, solution for injection, Nebido 1000 mg/4 ml injektionsvätska, lösning
Västra Götalandsregionen (VGR), Sahlgrenska Academy-Gothenburg University Institute, Västra Götalandregionen (VGR), Sahlgrenska Academy-Gothenburg University Institute
Delayed or absence of puberty Fördröjd eller utebliven pubertet, Young males with delayed or absence of puberty will be treated with testosterone replacement therapy Pojkar med fördröjd eller utebliven pubertet kommer att behandlas med testosterontillskott, Body processes [G] - Physiological processes [G07]
 
 
2007-005315-26: Sperm Suppression and Contraceptive Protection provived by Norethisterone Enantate (NET-EN) combined with Testosterone Undecanoate (TU) in healthy men.

 
2
110
Europe
Testosterone undecanoat, Noristerat, Nebido, Noristerat, Nebido
CONRAD, Eastern Virgina Medical School, CONRAD EASTERN VIRGINIA MEDICAL SCHOOL
The proposed study is designed to evaluate whether the combination of a progestin, norethisteroneenantate (NET-EN), and an androgen, testosterone undecanoate (TU), represents a safe and effectivemethod of male fertility regulation.
 
04/11
2010-021268-13: The Effects of Normalising Sex Hormone Levels in Obese Hypogonadal Men: A Prospective Randomized Comparator Controlled Parallel Arm Clinical Trial

Ongoing
2
90
Europe
Femara 2.5mg Tablets, Nebido 1000mg/4ml, solution for injection, Femara 2.5mg Tablets, Nebido 1000mg/4ml, solution for injection
University College Dublin
Obesity Related Male Hypogonadism
 
 
2018-002648-10: TestOsterone TreatmEnt in Relapsing Remitting Multiple Sclerosis Traitement de la SEP récurrente-rémittente (SEP-RR) par la testostérone

Not yet recruiting
2
80
Europe
Solution for injection, NEBIDO
Hôpitaux Universitaires de Strasbourg, DGOS, BAYER PHARMA AG, FHU Neurogenycs
Relapsing Remitting Multiple sclerosis Sclérose en Plaques Récurrente Rémittente, Multiple sclerosis Sclérose en Plaques, Diseases [C] - Nervous System Diseases [C10]
 
 
NCT04049331: Testosterone Replacement in Male Cancer Survivors with Fatigue and Low Testosterone

Recruiting
2
240
US
Testosterone Undecanoate 750 MG/3 ML Intramuscular Solution [AVEED], study drug, placebo
Seattle Institute for Biomedical and Clinical Research
Hypogonadism, Male, Fatigue Syndrome, Chronic
01/27
01/27
TOTEM-RRMS, NCT03910738: TOTEM RRMS : TestOsterone TreatmEnt on Neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis

Recruiting
2
40
Europe
Nebido® Testosterone Undecanoate 1000 Mg/4 mL Solution for Injection, Placebo 4 mL Solution for Injection, MRI, Assessment of impact of MS on cognition; quality of life; fatigue; anxiety/depression and work and activities, Assessment of disability
University Hospital, Strasbourg, France, Bayer, Fédération Hospitalo-Universitaire NEUROGENYCS, Grünenthal GmbH
Multiple Sclerosis, Relapsing-Remitting
12/27
12/27
T esters, NCT06393634: Comparing Direct and Indirect Detection Methods of Multiple Routes of Testosterone Administration

Completed
1
14
US
Testosterone injection, testosterone cipionate, enanthate,or propionate, Testosterone gel, testosterone transdermal, Testosterone Oral, testosterone undecanoate
Sports Medicine Research and Testing Laboratory
Healthy
11/24
11/24
ChiCTR1900024702: Clinical study for acupoint injection of chorionic gonadotropin in the treatment of late-onset hypogonadism in males

Not yet recruiting
N/A
60
 
Acupoint injection of HCG ;Intramuscular injection of HCG ;Oral testosterone undecanoate capsules
Guilin People's Hospital; Guilin People's Hospital, Scientific Research Project of Guangxi Medical and Health Self-financing(Z20190004)
Late-onset hypogonadism in males
 
 
ChiCTR2200062012: Acquired hypogonadism was treated with pulsed GnRH to reconstruct reproductive function

Not yet recruiting
N/A
120
 
Male patients treated with gonadotropin, including HCG preparation; In the HCG+HMG combined treatment period, HCG (2000u IM, 2-3 times a week) was given at the beginning of the method, and HMG(75-150u IM, 3 times a week) was added 3 months later according to the level of sex hormones, for 1 yea ;For both men and women, the same method can be used to pump subcutaneously at an interval of 90min with a single pulse initial dose of 5-10ug. If LH and/or FSH peak value ≤5Iu/L, increase by 5ug, the maximum dose is 25ug, and the course of treatment is 1 year ;Male should take testosterone undecanoate 40mg orally 3 days; Women received sequential estrogen progesterone therapy. ;Nothing
Second Affiliated Hospital of Army Military Medical University (Xinqiao Hospital) ; Second Affiliated Hospital of Army Military Medical University (Xinqiao Hospital), The subject is selected by the department
Acquired hypogonadism
 
 
EMRE, NCT05649605: Early Mental Response - The Study

Recruiting
N/A
70
Europe
Testosterone treatment, Nebido (3-oxandrostenderivate), testosterone undecanoate, Placebo treatment, Sodium chloride solution
Karolinska University Hospital
Gender Dysphoria, Gender Identity, Gender Issues
12/25
12/26
Versatis LE (lidocaine/diclofenac epolamine FDC patch) / Grunenthal
2016-002611-18: Lidocaine/diclofenac epolamine patch (GRT7019) Phase II proof-of-concept trial in patients with chronic pain due to knee osteoarthritis.

Ongoing
2
300
Europe
Lidocaine 700 mg / Diclofenac epolamine 182 mg Patch, GRT7019, Medicated plaster, Modified-release tablet, Gastro-resistant tablet, Versatis 5% medicated plaster, Diclo 75 SL - 1A Pharma, Pantoprazol-ratiopharm 20 mg
Grünenthal GmbH, Grünenthal GmbH
osteoarthritis, osteoarthritis, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
resiniferatoxin (GRT7039) / Grunenthal
2021-005046-15: Open-label trial to check the safety and tolerability of RTX-GRT7039 injections for pain associated with osteoarthritis of the knee.

Ongoing
3
715
Europe
RTX-GRT7039, Concentrate for solution for injection
Grünenthal GmbH, Grünenthal GmbH
Moderate to severe pain associated with Osteoarthritis of the knee, Pain due to osteoarthritis of the knee, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
2021-005029-26: Comparison of RTX-GRT7039 and placebo injections for pain associated with osteoarthritis of the knee.

Not yet recruiting
3
720
Europe, RoW
NA, Ropivacaina, RTX-GRT7039, Concentrate and solvent for solution for injection
Grünenthal GmbH, GRUNENTHAL GMBH, Grünenthal GmbH
Moderate to severe pain associated with osteoarthritis of the knee, Pain due to osteoarthritis of the knee, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
NCT05248386: Efficacy and Safety of RTX-GRT7039 in Adult Subjects With Knee Osteoarthritis

Completed
3
450
Europe, Canada, Japan, RoW
RTX-GRT7039, Placebo
Grünenthal GmbH
Osteoarthritis
11/24
11/24
NCT05449132 / 2021-005020-38: Comparison of a Single RTX-GRT7039 and Placebo Intra-articular Injection for Pain Associated With Osteoarthritis of the Knee

Completed
3
450
Europe, US
RTX-GRT7039, Placebo
Grünenthal GmbH, Grünenthal GmbH
Osteoarthritis
08/24
08/24
NCT05377489: Open-label Trial to Check the Safety and Tolerability of RTX-GRT7039 Injections for Pain Associated With Osteoarthritis of the Knee

Active, not recruiting
3
930
Europe, Japan, US, RoW
RTX-GRT7039
Grünenthal GmbH
Osteoarthritis
05/25
05/25
2017-004049-26: Lopain (MTX-071 / resiniferatoxin) Study to determine the safety and clinical effects of intra-articular injections of low doses of Lopain (MTX-071) in patients with chronic osteoarthritic knee joint pain

Ongoing
2
24
Europe
Lopain, MTX-071, Concentrate for solution for injection
Mestex, Mestex AG
chronic osteoarthritic knee-joint pain, Pain due to degenerative lesions of the knee joint, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
2018-000818-37: The pain reduction effects of different doses of Lopain (MTX-071) relative to placebo are evaluated in patients with chronic osteoarthritic knee joint pain. Porovnávanie efektu zníženia bolesti pri rôznych dávkach Lopainu (MTX-071) oproti placebu hodnoteného u pacientov s chronickou osteoartritídou kolenného kĺbu.

Ongoing
2
60
Europe, RoW
Lopain, MTX-071, Concentrate for solution for injection
Mestex AG, Mestex AG
chronic osteoarthritic knee joint pain, pain due to degenerative lesions of the knee joint, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
RTX-GRT7039 / Grunenthal
2021-005020-38: Comparison of a single RTX-GRT7039 and placebo intra-articular injection for pain associated with osteoarthritis of the knee. Demostrar la eficacia de una única inyección intraarticular de RTX-GRT7039 en comparación con el placebo para el dolor derivado de la gonartrosis

Ongoing
3
450
Europe
RTX-GRT7039, Concentrate for solution for injection
Grünenthal GmbH, Grünenthal GmbH
Moderate to severe pain associated with osteoarthritis of the knee Dolor de intensidad moderada a grave causado por una gonartrosis, Pain due to osteoarthritis of the knee Dolor asociado a una gonartrosis, Diseases [C] - Musculoskeletal Diseases [C05]
 
 

Download Options